Biotech Picks Up Pace In China While Investors Project Hong Kong Confidence
Doubling IPOs, Strong Sentiment But Concerns Loom
Beneath booming healthcare financing and deal-making in Asia is a constant flow of ready capital, but there are also challenges that may present hurdles to Hong Kong overtaking Nasdaq as the premier site for listings in the sector, a recent summit heard.
You may also be interested in...
Chinese CAR-T therapy developer raises new funds to progress pipeline in over-subscribed IPO which ranks as the third-largest globally in the biotech sector to date this year.
Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.
As a part of real-world evidence, patient-reported outcomes can serve to evaluate a drug's efficacy against primary or secondary endpoints and also reflect safety and quality of life, notes a just-released draft regulation from China’s Center for Drug Evaluation.